StudyRareStudyRare

CDKL5 deficiency disorder

Log in to star

Last updated Nov 15, 2026

Log in to add personal notes on this page.

A 3-month-old girl has had daily seizures since 5 weeks of age, first brief tonic events and now clusters of epileptic spasms, despite three antiseizure medications. She does not fix on faces or follow a light, and she is markedly hypotonic. Brain MRI is normal. Her parents and older brother are healthy.

X-linked; CDKL5 (cyclin-dependent kinase-like 5, a serine-threonine kinase, Xp22.13); loss of function.

  • About 99% simplex, most from a de novo germline variant (rarely postzygotic); rarely inherited from a heterozygous or mosaic mother
  • Females outnumber males about 4:1, yet a hemizygous male with a germline variant is usually severely affected; mosaic males and females can be mild
  • Sequence analysis detects about 84% of pathogenic variants and deletion/duplication analysis about 16%
  • Formerly called the early-seizure (Hanefeld) variant of Rett syndrome; the ILAE name is CDKL5-related developmental and epileptic encephalopathy
  • Estimated incidence 2.36 per 100,000 live births, from epilepsy panel testing of Scottish children

CDKL5 is a serine-threonine kinase expressed mainly in neurons, at the dendritic spines of excitatory synapses and in the nucleus, and its level rises after birth. It directly phosphorylates microtubule-binding proteins and interacts with the synaptic scaffold PSD-95.

Pathogenic variants are typically loss of function, and loss of kinase activity is the core defect: truncating variants and intragenic deletions remove function, and pathogenic missense variants cluster in the kinase domain. In models without CDKL5, neurons form fewer excitatory synapses, with less PSD-95, fewer AMPA-type and more NMDA-type glutamate receptors.

How this produces the epilepsy, the visual impairment, and the developmental disorder is not settled. Ongoing loss of CDKL5 function, damage during a critical developmental window, and the effects of intractable seizures may each contribute.

In females, severity also depends on X inactivation: a mother with favorably skewed inactivation can carry a variant with few or no signs. Duplications and rare gain-of-function missense variants cause different, usually milder, neurologic disease.

  • Epilepsy in more than 99%, typically starting in the first two months of life (up to age 12 months), with multiple seizures a day that resist antiseizure medications
  • Seizure types change over time: epileptic spasms are the first seizure type in about a quarter, half of them without hypsarrhythmia; tonic, focal, myoclonic, generalized tonic-clonic, and mixed spasm, tonic, and hypermotor seizures follow
  • Up to 40% have a temporary "honeymoon" improvement around ages 1 to 2 years
  • EEG can be normal in early infancy; the background later becomes abnormal, sometimes with a Lennox-Gastaut pattern
  • Severe developmental impairment in everyone: about 60% learn to sit, about 20% walk independently, and about 20% use spoken language
  • Cerebral (cortical) visual impairment in about 80%: poor fixation and tracking, nystagmus, abnormal response to bright light; it may improve with age
  • Hypotonia; hand stereotypies (hand to mouth, flapping), leg crossing, chorea, and dystonia
  • Sleep disturbance in about 90%; constipation and reflux; about 30% need a gastrostomy tube
  • Brain MRI often normal in the first year, later showing nonspecific cortical and cerebellar atrophy
  • Scoliosis and hip or knee subluxation
  • Suspect it in any infant, especially a girl, with epilepsy beginning in the first year of life plus motor and cognitive delay (the minimal clinical criteria proposed in 2019); seizures in the first two months and poor visual attention add weight
  • Confirm with an epilepsy multigene panel or exome sequencing; single-gene CDKL5 testing is rarely used now
  • Laboratory pitfalls: the transcript most expressed in brain (NM_001323289) carries 170 nucleotides at the end of its last exon that are noncoding in the transcripts long used for testing, and variants there have been missed; ask that the laboratory assess it. Mosaic variants need adequate sequencing depth. Intronic and 5' untranslated region variants occur, so consider genome sequencing when a panel or exome is negative.
  • Maternal testing helps classify a variant of uncertain significance, especially a missense variant outside the kinase domain
  • Versus Rett syndrome: seizures in the first months of life and cerebral visual impairment are not generally seen in classic Rett syndrome, which follows a period of normal development. Hand stereotypies in CDKL5 deficiency disorder (mouthing, flapping) are rarely like Rett hand-wringing and are more easily distracted.
  • Other developmental and epileptic encephalopathies to consider: KCNQ2 encephalopathy, Dravet syndrome, STXBP1, SCN2A, SCN8A, ARX, FOXG1, and PCDH19 disorders, MECP2 duplication syndrome, and Angelman syndrome
  • International consensus recommendations (Amin et al., Front Neurol 2022) guide care; a CDKL5 Center of Excellence can coordinate the many specialists involved
  • Ganaxolone (Ztalmy), a neuroactive steroid that positively modulates GABA-A receptors, was FDA approved in 2022 for seizures associated with CDKL5 deficiency disorder in patients 2 years and older, the first treatment approved for this disorder. In the phase 3 trial, the median 28-day frequency of major motor seizures fell 31% on ganaxolone and 7% on placebo over 17 weeks; somnolence is the main side effect.
  • Seizures usually stay refractory: balance control against side effects and aim for no more than two antiseizure medications
  • Feeding evaluation for choking, aspiration, poor weight gain, or meals longer than 30 minutes; gastrostomy when needed
  • Vision services for cerebral visual impairment; physical, occupational, and speech therapy with augmentative communication
  • Treat sleep disturbance, constipation, and reflux; watch the spine and hips, with orthopedic referral for a Cobb angle over 45 degrees
  • Annual review by primary care and specialists; plan the move to adult care from about age 10
  • Genetic counseling: test the mother. If she is heterozygous, each pregnancy carries a 50% chance of transmission; a daughter who inherits it is at high risk of being affected, and a son will most likely be severely affected. A negative maternal blood test does not remove the risk, because maternal germline mosaicism with sibling recurrence has been reported, so prenatal testing can be offered either way.

Reference Links